利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.019 秒)

    ICOTINIB-CONTAINING TOPICAL SKIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
    4.
    发明公开
    ICOTINIB-CONTAINING TOPICAL SKIN PHARMACEUTICAL COMPOSITION AND USE THEREOF 审中-公开
    ICOTINIBHALTIGE药物组合物，外用对皮肤及其用途

    公开(公告)号：EP3056206A1

    公开(公告)日：2016-08-17

    申请号：EP14851908.5

    申请日：2014-10-11

    申请人： Betta Pharmaceuticals Co., Ltd.

    发明人： WANG, Yinxiang ,  YUAN, Shujun ,  WANG, Yanping ,  HU, Shaojing ,  HU, Yunyan

    IPC分类号： A61K31/519 ,  A61K9/06 ,  A61P35/00 ,  A61P17/00

    CPC分类号： A61K31/519 ,  A61K9/0014 ,  A61K9/06

    摘要： Disclosed are topical preparations for inhibiting tyrosine kinase and preparation methods thereof, and especially topical pharmaceutical compositions for inhibiting tyrosine kinase and preparation methods thereof. The active ingredient of the topical preparations is Icotinib or a pharmaceutically acceptable salt thereof. The preparations are suitable for topical application, with minimal skin irritation, no adverse reactions such as pruritus, burning sensations, tingling, dry skin, erythema and rashes, without parahormone-related side effects such as skin atrophy, pigmentation or hypopigmentation for long-term use, as well as no related dermatological symptoms after drug withdrawal. The preparation methods are easily understood, operable, and controllable, and are suitable for industry mass production.

    摘要翻译： 本发明公开了局部制剂用于抑制酪氨酸激酶及其制备方法，和爱尤其局部用药物组合物用于抑制酪氨酸激酶及其制备方法。 局部制剂中的活性成分是埃克替尼或其药学上可接受的盐。 制剂为适合局部施用，以最小的皮肤刺激，无不良反应：如瘙痒，烧灼感，麻刺感，皮肤干燥，红斑和皮疹，无需对激素相关的副作用：如皮肤萎缩，色素沉着或色素沉着不足的长期 使用，以及停药后没有相关的皮肤症状。 制备方法很容易理解的，可互操作的，可控，并且适用于工业大批量生产。

    PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE
    5.
    发明公开
    PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE 审中-公开
    蛋白酪氨酸激酶调节剂及其使用方法

    公开(公告)号：EP3019489A1

    公开(公告)日：2016-05-18

    申请号：EP14822363.9

    申请日：2014-07-11

    申请人： Betta Pharmaceuticals Co., Ltd.

    发明人： HU, Shaojing ,  LIU, Xiangyong ,  BAI, Jinlong ,  LONG, Wei

    IPC分类号： C07D401/12 ,  C07D405/12 ,  C07D239/48 ,  C07D401/14 ,  A61K31/506 ,  A61P37/00 ,  A61P29/00

    CPC分类号： C07D401/12 ,  A61K31/33 ,  A61K31/395 ,  A61K31/495 ,  C07D239/48 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

    摘要： Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

    摘要翻译： 公开了调节突变选择性表皮生长因子受体（EGFR）和ALK激酶活性的杂环嘧啶化合物。 更具体地说，本发明提供了抑制，调节和/或调节激酶受体，尤其是选择性调节各种EGFR突变体活性和ALK激酶活性的嘧啶。 公开了包含嘧啶衍生物的药物组合物，以及治疗与蛋白激酶酶活性相关的疾病，特别是包括给予嘧啶衍生物的非小细胞肺癌的EGFR或ALK激酶活性的疾病的方法。